证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |--------------------------|---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------| | | | | | | | 特定对象调研 □分析师会议 | | | | | 媒体采访 □业绩说明会 | | | | 投资者关系 | □新闻发布会 | □路演活动 | | | 活动类别 | □现场参观 | 投资者接待日活动 | | | | □其他 | | | | 参与单位名称 及人员姓名 | 参加投资接待日的投资者 | | ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | --- | --- | |-------------------------|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|-------|--------| | | | | | | | | | | 特定对象调研 □分析师会议 | | | | | 投资者关系 | □新闻发布会 | 媒体采访 □业绩说明会 □路演活动 | | | | | 活动类别 | | □现场参观 □投资者接待日活动 | | | | | ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | --- | --- | |---------------------------|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | √特定对象调研 □分析师会议 | | | | | | □媒体采访 □业绩说明会 | | | | 投资者关系 | □新闻发布会 | □路演活动 | | | | 活动类别 | | □现场参观 □投资者接待日活动 | | | | | □其他 | | | | | 参与单位名称 及人员姓名 | | 浙商证券；方正富邦；国泰基 ...

证券代码：002099 证券简称：海翔药业 编号：2022-003 | --- | --- | --- | --- | |---------------------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------|--------------| | | | | | | | | 特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | | 投资者关系 | □新闻发布会 | □路演活动 | | | 活动类别 | | □现场参观 □投资者接待日活动 | | | | □其他 | | | | 参与单位名称 及人员姓名 | | 信达证券：阮帅、阙嘉程；泰康资产：马步云 | | | 时间 2022 | 年 7 月 12 日 | | | | | | 地点 浙江省台州市椒江区岩头工业区海虹路 71 | 号公司会议室 | | 上市公司接待 人员 ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | --- | --- | |---------------------------------------|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|-------|------------| | | | | | | | | | □特定对象调研 □分析师会议 | | | | | | 投资者关系 | □媒体采访 □业绩说明会 | | | | | | 活动类别 | □新闻发布会 | □路演活动 | ...

证券代码：002099 证券简称：海翔药业 浙江海翔药业股份有限公司投资者关系活动记录表 编号：2022-006 | --- | --- | --- | --- | --- | --- | |--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------|---------- ...

浙江海翔药业股份有限公司 2022 年第三季度报告 证券代码：002099 证券简称：海翔药业 公告编号：2022-041 浙江海翔药业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 浙江海翔药业股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|--------- ...

Financial Performance - Zhejiang Haixiang Pharmaceutical reported a revenue of 1.2 billion CNY for the first half of 2022, representing a year-on-year increase of 15%[20]. - The company's net profit attributable to shareholders reached 200 million CNY, up 10% compared to the same period last year[20]. - The company has set a performance guidance of 1.5 billion CNY in revenue for the full year 2022, reflecting a growth target of 20%[20]. - The company's operating revenue for the reporting period was 1.468 billion yuan, representing a year-on-year increase of 23.46%[44]. - Net profit attributable to shareholders was 146.78 million yuan, up 183.71% compared to the same period last year[44]. - The pharmaceutical segment generated revenue of 1.027 billion yuan, with a year-on-year growth of 51.90%[44]. - The company's total operating revenue for the reporting period was ¥1,467,811,588.79, representing a year-on-year increase of 23.46% compared to ¥1,188,867,441.13 in the same period last year[52]. - The company has set a performance guidance of 1.5 billion RMB in revenue for the full year 2022, indicating a growth target of 20%[26]. Research and Development - The company has allocated 150 million CNY for R&D in 2022, which is a 30% increase from the previous year[20]. - Hisoar is investing 100 million RMB in R&D for new technologies aimed at improving drug efficacy and safety[26]. - The company invested 72.09 million yuan in R&D during the reporting period, conducting 38 research projects[45]. - New product development includes a pipeline of 5 innovative drugs expected to enter clinical trials by Q4 2022[20]. - Hisoar plans to launch three new products in the next quarter, focusing on innovative drug formulations[26]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2023[20]. - Market expansion efforts include entering two new international markets, targeting a 25% increase in overseas sales by the end of 2022[26]. - The company aims to expand its market presence by developing new products and enhancing collaboration in the pigment and new materials sectors[50]. Strategic Acquisitions - Haixiang Pharmaceutical is pursuing strategic acquisitions to enhance its product portfolio, with a focus on companies specializing in biopharmaceuticals[20]. - Hisoar is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[26]. Financial Position - The total assets at the end of the reporting period were 8.404 billion yuan, a 4.79% increase from the end of the previous year[44]. - Cash and cash equivalents at the end of the reporting period amounted to ¥1,568,907,352.80, accounting for 18.67% of total assets, a decrease of 4.12% from the previous year[59]. - Accounts receivable reached ¥561,881,283.28, representing 6.69% of total assets, an increase of 0.59% year-on-year[59]. - Inventory stood at ¥1,004,960,652.83, which is 11.96% of total assets, reflecting a 0.64% increase compared to the previous year[59]. - Short-term borrowings increased significantly to ¥1,047,810,513.88, making up 12.47% of total assets, a rise of 5.36% due to increased bank loans during the period[59]. Environmental and Social Responsibility - The company has implemented measures to enhance environmental protection and safety production management, ensuring no major incidents have occurred[90]. - The company actively participates in social welfare initiatives, demonstrating a strong sense of social responsibility while achieving sustainable development[125]. - The company has established comprehensive emergency response plans for environmental incidents, with regular training and drills for employees[120]. - The company has implemented advanced real-time monitoring systems for waste gas and VOCs, ensuring compliance with emission standards[118]. Shareholder and Corporate Governance - The company emphasizes the protection of shareholder rights, adhering to relevant laws and regulations to enhance corporate governance and ensure the legitimate rights of shareholders, especially minority investors[123]. - The company has established a comprehensive employee rights protection system, providing various benefits and ensuring timely payment of social insurance and housing funds[125]. - The company has not sold any major assets during the reporting period[82]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[132]. Challenges and Risks - The company faces significant risks from industry policies, exchange rate fluctuations, raw material price volatility, environmental protection, and talent shortages[88][90]. - The dye industry is currently in a downturn, with terminal demand remaining sluggish, affecting profitability in the dye segment[86].

Financial Performance - The company's revenue for Q1 2022 was ¥804,527,527.52, representing a 25.26% increase compared to ¥642,309,773.93 in the same period last year[3] - Net profit attributable to shareholders was ¥87,024,150.17, up 52.17% from ¥57,187,894.76 year-on-year[3] - Basic earnings per share rose to ¥0.05, a 25.00% increase from ¥0.04 in the same period last year[3] - Net profit for the current period was ¥86,547,687.52, representing a 52.5% increase compared to ¥56,846,105.31 in the same period last year[21] Cash Flow and Operating Activities - The net cash flow from operating activities increased by 21.40% to ¥149,627,750.29, compared to ¥123,247,740.86 in the previous year[3] - Cash flow from operating activities generated ¥149,627,750.29, compared to ¥123,247,740.86 in the previous period, marking a 21.4% increase[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,991,182,946.80, a slight decrease of 0.36% from ¥8,019,943,288.69 at the end of the previous year[4] - Total liabilities decreased to CNY 1.77 billion from CNY 1.91 billion, showing a reduction of approximately 6.9%[17] - The company's equity attributable to shareholders increased to CNY 6.22 billion from CNY 6.12 billion, marking a growth of about 1.8%[17] Investment and Income - The company reported a significant increase in investment income, which rose by 401.24% to ¥5,823,939.13, compared to a loss of ¥1,933,295.84 in the previous year[8] - Other income increased to ¥3,365,583.75 from ¥2,151,254.54, a growth of 56.4%[21] Operating Costs and Expenses - The company's operating costs increased by 48.93% to ¥563,342,170.57, primarily due to increased sales volume and rising unit costs[8] - Total operating costs amounted to ¥707,999,096.02, up 25.8% from ¥562,351,791.33 in the prior period[20] - Research and development expenses decreased to ¥34,757,233.67 from ¥40,190,992.54, a reduction of 13.5%[20] - Sales expenses rose to ¥5,399,712.63, up 33.1% from ¥4,058,842.43 in the previous period[20] - Management expenses decreased significantly to ¥94,783,985.19 from ¥144,335,911.74, a decline of 34.4%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,629, with the largest shareholder holding 32.37% of the shares[9] Cash and Cash Equivalents - Current assets increased slightly to CNY 3.45 billion from CNY 3.44 billion, with cash and cash equivalents at CNY 1.71 billion, down from CNY 1.83 billion[14] - The ending balance of cash and cash equivalents was 1,609,701,019.10 CNY in Q1 2022, compared to 2,150,460,400.33 CNY in Q1 2021[25] Borrowings and Financing Activities - The company received 100,000,000.00 CNY in borrowings during Q1 2022, down from 210,000,000.00 CNY in Q1 2021[25] - The company paid 104,572,083.35 CNY in cash outflows related to financing activities in Q1 2022, compared to 13,844,486.12 CNY in Q1 2021[25] Audit Information - The company did not conduct an audit for the Q1 2022 report[26]

Financial Performance - The company's operating revenue for 2021 was CNY 2,484,828,437.08, representing a year-on-year increase of 0.54% compared to CNY 2,471,386,626.07 in 2020[28]. - The net profit attributable to shareholders in 2021 was CNY 95,229,600.22, a decrease of 70.21% from CNY 319,715,246.00 in 2020[28]. - The net cash flow from operating activities was CNY 102,360,758.31, down 80.83% from CNY 533,869,722.35 in the previous year[28]. - Basic earnings per share for 2021 were CNY 0.06, a decline of 70.00% compared to CNY 0.20 in 2020[28]. - Total assets at the end of 2021 were CNY 8,019,943,288.69, an increase of 11.72% from CNY 7,178,568,316.07 at the end of 2020[30]. - The net assets attributable to shareholders at the end of 2021 were CNY 6,115,000,722.08, up 4.49% from CNY 5,852,085,567.11 at the end of 2020[30]. - The company's weighted average return on equity was 1.59% in 2021, a decrease of 4.20 percentage points from 5.79% in 2020[28]. - The net profit after deducting non-recurring gains and losses was CNY 63,366,304.02, down 78.62% from CNY 296,446,725.20 in 2020[28]. - Total revenue for 2021 was approximately ¥2.48 billion, a slight increase of 0.54% compared to ¥2.47 billion in 2020[72]. - The pharmaceutical segment generated ¥1.48 billion, accounting for 59.72% of total revenue, showing a decrease of 3.36% from ¥1.54 billion in 2020[72]. - The dye segment reported revenue of ¥988.6 million, representing 39.79% of total revenue, with a growth of 6.31% from ¥930 million in 2020[72]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1.00 CNY per 10 shares (including tax) based on a total of 1,618,715,253 shares[8]. - The total distributable profit for the year is reported at 1,410,822,380.90 CNY[166]. - The employee stock ownership plan includes 484 employees holding a total of 63,005,888 shares, representing 3.89% of the company's total equity[167]. - The company confirmed a share-based payment amount of 20,035,870 CNY related to the employee stock ownership plan during the reporting period[171]. - The cash dividend distribution plan is compliant with the company's articles of association and shareholder resolutions[166]. Research and Development - The company invested 165 million RMB in R&D in 2021, a year-on-year increase of 24.75%, and completed over 30 development projects[45]. - The company has a strong focus on R&D, with 62 domestic invention patents and 4 PCT patents, and has completed 13 national-level projects[65]. - The company aims to expand its product pipeline with multiple new drug approvals expected in the near future, targeting new growth points[83]. - The company is focusing on expanding its pharmaceutical product lines and enhancing its research and development capabilities to drive future growth[137]. - The company is committed to innovation in drug development, leveraging its research capabilities to introduce new therapies[138]. Market and Business Strategy - The company is focused on expanding its market presence and enhancing its product offerings through innovation[18]. - The company is exploring market opportunities in the antiviral field, with a well-structured product lineup and a new growth cycle taking shape[42]. - The company has formed strategic partnerships with international pharmaceutical giants to expand its market share in high-end products[43]. - The company aims to increase its market share in both domestic and international markets through strategic partnerships and collaborations[137]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and broaden its product offerings[137]. Risk Management - The company has outlined potential risks in its future development outlook section, which investors should pay attention to[8]. - The company has a comprehensive risk management strategy in place to address potential operational challenges[8]. - The company faces risks from exchange rate fluctuations, which could impact revenue from export business settled in foreign currencies[119]. - The company is exposed to raw material price volatility, which could adversely affect profitability if costs cannot be passed on to customers[119]. - Safety risks are present due to complex production processes involving high temperatures and toxic gases, which could lead to accidents[119]. Environmental Responsibility - The company has reported a commitment to environmental and social responsibility in its operations[11]. - The company has reduced wastewater emissions by over 80% for certain products through process optimization and new technologies[45]. - The company has implemented various environmental protection facilities, including wastewater, waste gas, and solid waste treatment, which are operating normally and effectively reducing pollutant emissions[192]. - The company has achieved zero emissions for COD, ammonia nitrogen, sulfur dioxide, nitrogen oxides, VOCs, and particulate matter in its operations[192]. - The company has received environmental impact assessment approvals for multiple projects, including a 100-ton production capacity for Dabigatran etexilate and a 5000-ton capacity for low B salt Lincomycin[193]. Governance and Compliance - The company maintains a transparent governance structure, ensuring compliance with relevant laws and regulations[123]. - The company has established an independent financial accounting system and management practices, ensuring autonomous financial operations[127]. - The company has implemented a performance assessment mechanism linking senior management remuneration to company performance[145]. - The company has a structured governance framework with independent directors and a clear separation of roles[132]. - The company has not encountered any significant issues in the integration of subsidiaries during the reporting period[173]. Employee Management - The total number of employees at the end of the reporting period was 2,899, with 341 in the parent company and 2,558 in major subsidiaries[160]. - The company emphasizes employee training, implementing annual training plans focused on cGMP, safety production, professional knowledge, and management skills[162]. - The company has implemented a stable and competitive compensation system for its employees[161]. - The company strictly adheres to national labor laws and provides competitive salaries along with a fair performance evaluation mechanism[161]. - The company has a total of 14 senior management personnel, with an average remuneration of approximately CNY 61.07 million per person[146].